KOL Perspectives: Perceptions of Lupus Pipeline Therapy Data Presented at EULAR 2018
Summary
This KOL Insight briefing focuses on KOLs views of Pipeline Therapy Data Presented at EULAR 2018.
Questions topics
Opinion on abatacept failing to achieve its primary endpoint in its Phase III LN trial
Views on the Phase III safety data for abatacept in LN
Expectations regarding abatacept's future development in lupus
Opinion on ustekinumab's ability to achieve partial improvements using SLEDAI2K Responder Index50
Views on ustekinumab's Phase III trial design
Views on the absence of safety endpoints in the Phase III ustekinumab trial in SLE
Perception of etanercept's efficacy in discoid lupus erythematosus
Opinion on etanercept's safety data from the Phase II TARGETDLE trial
Key Highlights
While most KOLs agreed that abatacept's future in LN is uncertain, half of the KOLs highlighted that the drug has potential in lupus arthritis
Most KOLs highlighted that SLEDAI2K Responder Index50 data supports ustekinumab use in SLE
While most KOLs flagged that etanercept may exacerbate lupus features, half of the KOLs highlighted that etanercept has potential in lupus.
Scope
The insight briefing is based on Sociable Pharma's analysis of primary research with our Lupus key opinion leaders KOLs.
In total, we conducted interviews with 10 KOLs
5 Europebased 5 N. Americabased
Interviews performed during Aug 2018
KOL data is analyzed to produce
Charts summarizing KOL opinions
Chart callouts of key information details
KOL quotes
Summary of KOL reporting trends
Insight from Sociable Pharma's analysts
Reasons to buy
Combines Qualitative semiquantitative insight from key opinion leaders on Pipeline Therapy Data Presented at EULAR 2018
Includes insight recommendations from our diseasespecific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of new clinical data emerging trends on management of Lupus
Provides costeffective support for your advisory boards, with topics acting as a catalyst for further expert discussion.